What is Bicycle Therapeutics Plc - ADR Annual Revenue?

Bicycle Therapeutics Plc - ADR Annual Revenue rose 30.76%, in the last year to $35.28 M. Its sector's average revenue growth for the last fiscal year was 7.47%.

What is Bicycle Therapeutics Plc - ADR Annual Net Profit?

Bicycle Therapeutics Plc - ADR Annual Net Profit rose 6.44% in the last year to $169.03 M. Its sector's average net profit growth for the last fiscal year was -32.35%.

What is Bicycle Therapeutics Plc - ADR Price to Earning Ratio?

Bicycle Therapeutics Plc - ADR Price to Earning Ratio is -3.81, which is negative.

What is Bicycle Therapeutics Plc - ADR Stock Price?

Bicycle Therapeutics Plc - ADR Stock Price fell 63.65% and underperformed its sector by 72.76% in the past year.

What is Bicycle Therapeutics Plc - ADR Quarterly Revenue?

Bicycle Therapeutics Plc - ADR Quarterly Revenue fell 30.44% YoY to $3.71 M. Its sector's average revenue growth YoY for the quarter was 5.96%.

What is Bicycle Therapeutics Plc - ADR Quarterly Net profit?

Bicycle Therapeutics Plc - ADR Quarterly Net profit fell 5.61% YoY to $51.85 M. Its sector's average net profit growth YoY for the quarter was -47.35%.

What is Bicycle Therapeutics Plc - ADR Debt to Equity Ratio?

Bicycle Therapeutics Plc - ADR Debt to Equity Ratio of 0.01 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

What is Bicycle Therapeutics Plc - ADR Return on Equity(ROE)?

Bicycle Therapeutics Plc - ADR Return on Equity(ROE) for the last financial year was -29.04%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is Bicycle Therapeutics Plc - ADR Mutual Fund Holding?

Bicycle Therapeutics Plc - ADR Mutual Fund Holding increased by 0.61% in the last quarter to 14.07.

What is Bicycle Therapeutics Plc - ADR Interest Coverage Ratio?

Bicycle Therapeutics Plc - ADR Interest Coverage Ratio is -99.46, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

What is Bicycle Therapeutics Plc - ADR Institutional Holding?

Bicycle Therapeutics Plc - ADR Institutional Holding decreased by 5.61% in the last quarter to 60.59.

How is the Bicycle Therapeutics Plc - ADR today?

The Bicycle Therapeutics Plc - ADR today is trading in the down by -1.90% at 9.31.

How has Bicycle Therapeutics Plc - ADR performed historically?

The Bicycle Therapeutics Plc - ADR is currently trading down -1.90% on an intraday basis in the past week the index fell -3.32%. The index has been down -37.56% in the past quarter and fell -63.65% in the past year. You can view this in the overview section.

Bicycle Therapeutics Plc - ADR XNAS: BCYC

Bicycle Therapeutics Plc - ADR Live Share Price Today, Share Analysis and Chart

Name: Bicycle Therapeutics Plc - ADR: Is Infosys Ltd. worth buying?
Item: Bicycle Therapeutics Plc - ADR
Rating: 1.102138875
Author: Trendlyne DVM scores

Weak Stock

Download real time

9.31 -0.18 (-1.90%)

New 52W Low in past week

84,967 XNAS Volume

XNAS 21 Mar, 2025 12:15 PM (EDT)

Bicycle Therapeutics Plc -... Key Metrics

My Metrics

Default

Market Capitalization Below industry Median Unavailable in chosen country	644.3
PE TTM Negative PE TTM Unavailable in chosen country	-3.8
PEG TTM Negative PEG TTM Unavailable in chosen country	-0.6
Price to Book Below industry Median Unavailable in chosen country	0.8
Institutional holding current Qtr % Below industry Median Unavailable in chosen country	60.6
Revenue Growth Qtr YoY % Negative Revenue Growth Qtr YoY % Unavailable in chosen country	-30.4
Operating Revenue growth TTM % Below industry Median Unavailable in chosen country	30.8
Net Profit Qtr Growth YoY % Negative Net Profit Qtr Growth YoY % Unavailable in chosen country	-5.6
Net Profit TTM Growth % Below industry Median Unavailable in chosen country	6.4
Operating Profit Margin Qtr % Negative Operating Profit Margin Qtr % Unavailable in chosen country	-1,809.4
Operating Profit Margin TTM % Negative Operating Profit Margin TTM % Unavailable in chosen country	-592.9
Piotroski Score Below industry Median Unavailable in chosen country	2
Rel Perf vs Sector quarter% Unavailable in chosen country	-46.2
ROE Annual % Negative ROE Annual % Unavailable in chosen country	-29
RoA Annual % Negative RoA Annual % Unavailable in chosen country	-21.8

All financials are in USD Million and price data in USD

Low Financial Strength

22.2 / 100

Expensive Valuation

16.2 / 100

Technically Bearish

27.6 / 100

Weak Stock These stocks are the ones with poor quality, financials and technicals. This indicates that investors should be highly watchful with these stocks. View Similar Embed DVM

1Yr Price target upside is 217%

11 analysts

Check Before You Buy

Check P/E Buy Sell Zone

This stock has negative PE

Bicycle Therapeutics Plc -... Stock Price Analysis

Day Price Range -1.9% 1 Day return Unavailable in chosen country	9.3 (LTP) 9.29.7 LowHigh
Week Price Range -3.3% 1 Week return Unavailable in chosen country	9.3 (LTP) 910.3 LowHigh
Month Price Range -22.4% 1 Month return Unavailable in chosen country	9.3 (LTP) 912.6 LowHigh
52 Week Price Range -63.6% 1 Year return Unavailable in chosen country	9.3 (LTP) 928.7 LowHigh

View full Share Price History

Bicycle Therapeutics Plc -... Live Price Chart

Switch to TradingView

Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Miss

Bicycle Therapeutics Plc - ADR's Revenue was lower than average estimate 3 times in past 3 years

EPS forecast

QUARTER
ANNUAL

Current EPS

-2.9

Avg. Estimate

-3.5

Low Estimate

-4

High Estimate

-2.8

Current EPS

Avg. Estimate

Miss

EPS is expected to reduce by 20.3% in FY25

Consensus Recommendation

13 ANALYST Recommendations

BUY

The consensus recommendation from 13 analysts for Bicycle Therapeutics Plc - ADR is BUY

Forecaster is a Premium Feature

You need to upgrade your subscription plan to access this feature

Upgrade Now

Bicycle Therapeutics Plc -... Stock Analysis

Bicycle Therapeutics Plc -... stock analysis with key metrics, changes, and trends.

Bicycle Therapeutics Plc -... Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Revenue	$35.28 M	30.76%	positive	Annual Revenue rose 30.76%, in the last year to $35.28 M. Its sector's average revenue growth for the last fiscal year was 7.47%.
Annual Net Profit	$169.03 M	6.44%	positive	Annual Net Profit rose 6.44% in the last year to $169.03 M. Its sector's average net profit growth for the last fiscal year was -32.35%.
Price to Earning Ratio	-3.81	-	negative	Price to Earning Ratio is -3.81, which is negative.
Stock Price	$9.31	-63.65%	negative	Stock Price fell 63.65% and underperformed its sector by 72.76% in the past year.
Quarterly Revenue	$3.71 M	30.44%	negative	Quarterly Revenue fell 30.44% YoY to $3.71 M. Its sector's average revenue growth YoY for the quarter was 5.96%.
Quarterly Net profit	$51.85 M	5.61%	negative	Quarterly Net profit fell 5.61% YoY to $51.85 M. Its sector's average net profit growth YoY for the quarter was -47.35%.
Debt to Equity Ratio	0.01	-	positive	Debt to Equity Ratio of 0.01 is less than 1 and healthy. This implies that its assets are financed mainly through equity.
Return on Equity(ROE)	-29.04 %	-29.04%	negative	Return on Equity(ROE) for the last financial year was -29.04%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.
Mutual Fund Holding	14.07 %	0.61%	positive	Mutual Fund Holding increased by 0.61% in the last quarter to 14.07.
Interest Coverage Ratio	-99.46	-	negative	Interest Coverage Ratio is -99.46, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).
Institutional Holding	60.59 %	-5.61%	negative	Institutional Holding decreased by 5.61% in the last quarter to 60.59.

VIEW LESS

Loading data..

Bicycle Therapeutics Plc - ADR - Company Profile

What does Bicycle Therapeutics Plc - ADR do?

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.

Gross Remuneration

2024

Gross Remuneration

Year

Bicycle Therapeutics Plc - ADR Live Share Price Today, Share Analysis and Chart

New 52W Low in past week

Bicycle Therapeutics Plc -... Key Metrics

Market Capitalization

PE TTM

PEG TTM

Rel Perf vs Sector quarter%

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

ROE Annual %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

RoA Annual %

Operating Profit Margin Qtr %

Operating Profit Margin TTM %

Piotroski Score

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Operating Profit Margin Qtr %

Operating Profit Margin TTM %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

Bicycle Therapeutics Plc -... Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

Bicycle Therapeutics Plc -... Live Price Chart

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Bicycle Therapeutics Plc - ADR's Revenue was lower than average estimate 3 times in past 3 years

EPS forecast

EPS is expected to reduce by 20.3% in FY25

Consensus Recommendation

The consensus recommendation from 13 analysts for Bicycle Therapeutics Plc - ADR is BUY

Bicycle Therapeutics Plc -... Stock Analysis

Bicycle Therapeutics Plc -... stock analysis with key metrics, changes, and trends.

Annual Revenue rose 30.76%, in the last year to $35.28 M. Its sector's average revenue growth for the last fiscal year was 7.47%.

Annual Net Profit rose 6.44% in the last year to $169.03 M. Its sector's average net profit growth for the last fiscal year was -32.35%.

Price to Earning Ratio is -3.81, which is negative.

Stock Price fell 63.65% and underperformed its sector by 72.76% in the past year.

Quarterly Revenue fell 30.44% YoY to $3.71 M. Its sector's average revenue growth YoY for the quarter was 5.96%.

Quarterly Net profit fell 5.61% YoY to $51.85 M. Its sector's average net profit growth YoY for the quarter was -47.35%.

Debt to Equity Ratio of 0.01 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE) for the last financial year was -29.04%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding increased by 0.61% in the last quarter to 14.07.

Interest Coverage Ratio is -99.46, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

Institutional Holding decreased by 5.61% in the last quarter to 60.59.

Bicycle Therapeutics Plc - ADR - Company Profile

What does Bicycle Therapeutics Plc - ADR do?

Bicycle Therapeutics Plc - ADR Management structure

Dr. Kevin Lee, M.B.A.

Director and Chief Executive Officer

Ms. Alethia Young

Chief Financial Officer

Mr. Travis Thompson

Chief Accounting Officer

Bicycle Therapeutics Plc - ADR Board of directors

Mr. Stephen Sands

Independent Director

Mr. Pierre Legault, C.P.A.,M.B.A.

Chairman of the Board

Mr. Richard N. Kender, M.B.A.

Independent Director

Dr. Felix J. Baker,PhD

Independent Director